U.S. Cell‑Therapy Delivery Still Depends on Outdated Infrastructure
Apheresis Capacity at a Crossroads: Why U.S. Cell‑Therapy Delivery Still Depends on Outdated Infrastructure
Autologous cell therapies depend on apheresis collections that meet manufacturing‑grade quality expectations — but the U.S. collection ecosystem was never built for that purpose. Blood centers operate under transfusion‑era regulations, hospital apheresis units prioritize clinical care, and CDMOs expect GMP‑aligned starting material. The result is a structural mismatch that affects scheduling, chain‑of‑identity, and ultimately patient access. Recent national data and professional‑society standards make the gap clear: the U.S. apheresis system is not yet aligned with the demands of modern cell therapy.
Financial and Historical Backdrop: Apheresis Built for Transfusion, Not Manufacturing
The U.S. apheresis infrastructure grew out of transfusion medicine, not advanced therapy manufacturing. Blood centers operate under 21 CFR 606, which governs blood establishments, while cell‑therapy manufacturing aligns with 21 CFR 1271 and GMP expectations. These frameworks differ in scope, documentation, and quality oversight.
Professional societies have acknowledged this gap. The AABB Standards for Cellular Therapy Services (9th ed.) state:
“Collection facilities shall maintain a quality management system that ensures traceability, documentation, and control of cellular therapy products.”
(AABB, 2022)
This requirement reflects a manufacturing‑grade QMS — something many blood centers were not originally designed to support.
National data reinforce the strain. The 2021 National Blood Collection and Utilization Survey (NBCUS) reported:
“Staffing shortages were reported by 62% of responding blood centers, affecting both collection and processing activities.”
(NBCUS, 2023)
These shortages directly affect the availability of trained apheresis staff, limiting the system’s ability to absorb new cell‑therapy demand.
Operational Legacy: When Clinical Apheresis Meets Manufacturing Requirements
Clinical apheresis units were built to support patient care — urgent therapeutic procedures, platelet collections, and plasma exchange — not to serve as the front end of a GMP manufacturing chain. This legacy creates friction in several operational domains:
1. Documentation and QMS alignment
FACT‑JACIE standards emphasize manufacturing‑grade documentation:
“Collection facilities shall have documented procedures to ensure chain of identity and chain of custody from the time of collection through release.”
(FACT‑JACIE, 2021)
Many clinical apheresis units rely on EHR‑based identifiers and clinical documentation workflows that do not integrate with sponsor COI/COC systems.
2. Starting‑material quality expectations
The FDA’s CAR‑T guidance makes the stakes explicit:
“The quality of the starting material is critical to the success of manufacturing autologous CAR T cell products.”
(FDA, 2020)
Sponsors, therefore, require detailed batch‑record‑like documentation, deviation reporting, and environmental controls — expectations that exceed typical clinical practice.
3. Variability in leukapheresis collections
Peer‑reviewed literature confirms that collection‑site variability is a major manufacturing risk. Harrison et al. (2021) note:
“Variability in leukapheresis collections remains a major source of manufacturing failure in autologous cell therapies.”
(Drug Discovery Today, 2021)
This variability stems from differences in equipment, staff training, anticoagulation protocols, and patient preparation — all of which are tightly controlled in GMP environments but variable in clinical settings.
Supply‑Chain Fragility: Pandemic Lessons and Persistent Constraints
The COVID‑19 pandemic exposed the fragility of the U.S. apheresis and cell‑therapy supply chain. NBCUS 2021 data documented widespread operational strain, including staffing shortages, reduced collection volumes, and logistical disruptions (NBCUS, 2023). These challenges affected both transfusion and therapeutic apheresis, with downstream consequences for scheduled autologous collections.
Industry analyses echo these concerns. Informa Connect’s 2022 white paper states:
“Autologous cell therapy supply chains are uniquely vulnerable due to their reliance on patient‑specific starting material and just‑in‑time scheduling.”
(Informa Connect, 2022)
This vulnerability is amplified when collection sites lack the QMS infrastructure needed to meet sponsor requirements.
NMDP BioTherapies, which operates one of the largest apheresis networks in the U.S., highlights the heterogeneity of collection‑site capabilities:
“Collection centers vary significantly in their experience, staffing, and ability to meet sponsor‑defined requirements for cellular starting material.”
(NMDP BioTherapies, 2022)
This variability creates bottlenecks, especially in regions without FACT‑accredited centers or where blood centers lack the resources to upgrade their QMS.
Global guidance reinforces the structural mismatch. The WHO Good Practices for Blood Establishments (2020) state:
“Blood establishments are not manufacturing facilities and may not have the systems required for advanced therapy medicinal products.”
(WHO, 2020)
This is perhaps the clearest acknowledgment that the transfusion‑era infrastructure is not aligned with the needs of cell‑therapy manufacturing.
Patient‑Access Impacts: When Infrastructure Limits Therapy Availability
The misalignment between clinical apheresis infrastructure and manufacturing requirements has direct consequences for patients:
Delayed collections can push patients outside eligibility windows or compromise disease control.
Inconsistent starting‑material quality can reduce manufacturing success rates, leading to product failures or repeat collections.
Geographic disparities limit access for patients in regions without qualified collection centers.
Administrative burden increases for hospitals navigating sponsor manuals, COI systems, and QMS expectations.
Professional societies have warned that cell‑therapy access depends on strengthening the collection‑to‑manufacturing interface. AABB and ASH emphasize the need for standardized documentation, improved training, and closer coordination between clinical and manufacturing entities (AABB, 2022; ASH, 2021).
Ultimately, the U.S. cell‑therapy ecosystem is constrained not by scientific innovation but by infrastructure built for a different era.
Conclusion
Autologous cell therapies have outpaced the infrastructure that supports them. The U.S. relies on apheresis systems designed for transfusion medicine, not for GMP‑aligned manufacturing inputs. Pandemic‑era disruptions highlighted the fragility of this model, and national data confirm that capacity constraints persist. Until collection‑site QMS, scheduling models, and supply‑chain coordination are modernized, patient access will remain uneven and manufacturing risk will remain high.
References (APA)
AABB. (2022). Standards for Cellular Therapy Services (9th ed.).https://www.aabb.org/standards
FACT‑JACIE. (2021). International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration (8th ed.). https://www.factglobal.org
FDA. (2020). Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products.https://www.fda.gov/media/136703/download
Harrison, R., et al. (2021). Supply chain challenges in autologous cell therapy manufacturing. Drug Discovery Today, 26(11), 2737–2745. https://doi.org/10.1016/j.drudis.2021.08.010
Informa Connect. (2022). Cell and Gene Therapy Supply Chain Outlook.https://pharmaintelligence.informa.com
National Blood Collection and Utilization Survey (NBCUS). (2023). 2021 Report.https://www.hhs.gov/ash/blood-safety/nbcus/index.html
NMDP BioTherapies. (2022). Apheresis Network Capabilities Overview.https://nmdp.org/biotherapies
World Health Organization. (2020). Good Practices for Blood Establishments (Annex 4).https://www.who.int/publications/m/item/trs1020-annex-4
